The IMF's Signature Project to Find a Cure

The Black Swan Research Initiative (BSRI) was established following a scientific brainstorming meeting linked to the IMWG Summit held in Amsterdam in 2012. The meeting occurred in a remote boathouse to ensure privacy and an excellent focus on the task at hand! The question posed to the brainstorming team was "How can we cure myeloma?" The answer: "Establish a new research project focused on both finding a cure and preventing myeloma in the first place." 

The key recommendation was to establish and standardize methods for assessment of the lowest levels of myeloma after best treatment—so called Minimal Residual Disease (MRD) testing. Precise, sensitive, and reproducible MRD testing is essential to adequately monitor best treatments to assess if cure is being achieved or not. And so began the Black Swan Research Initiative—the ambitious plan to finance and establish research to achieve a cure.


black swanWhy “Black Swan”?

To achieve a cure we clearly needed to "think outside the box," and keep an open mind to all avenues of research. A striking example of keeping an open mind is the thinking about "What color is a swan?"

In the developing Western world, swans were WHITE. Then suddenly in 1697, sailing up the Swan (or Swanee) River in Western Australia, BLACK SWANS were spotted—something nobody had imagined possible. Definitely, quite a surprise!

Swans, it turns out, occur around the world in a variety of colors, but black is the most striking.  A Black Swan Event is a metaphor for an unexpected event that can have a major impact. The research team then decided that the name Black Swan captures the intent to open our minds to ALL potentially important research findings and capitalize on ALL opportunities—unexpected or not. These opportunities can have a major impact in the search for the cure. 

Undoubtedly, the biggest surprise we want to uncover as BSRI team is the cure for myeloma in our lifetimes and the ability to restore myeloma patients to a normal, healthy lifestyle that is free of cancer.

A Multinational Consortium of Myeloma Experts

The first BSRI project was with the University of Salamanca in Spain. Its aim was to develop the much-needed precise, sensitive, and cost-efficient MRD test known as Next Generation Flow MRD testing. Today, more than 50 projects are occurring to achieve the basic and translational research that is needed to move closer and closer to a cure .


An Orchestrated Effort

Black Swan Research Initiative lgoo

An orchestra can only succeed if each diverse and talented member plays well together in the spirit of achieving one synchronized outcome. The conductor leads and sends out signals to each player to encourage working together. In this sense, the IMF's Black Swan Research Initiative serves as a conductor of sorts to this orchestra of collaborating experts in the field of myeloma. The BSRI sponsors more than 50 projects around the world aimed at curing multiple myeloma. Among them....


The CESAR trial uses the combination of Kyprolis, Revlimid, and dexamethasone plus autologous stem-cell transplant to treat high-risk smoldering multiple myeloma. It applies:

  • Precise mininal residual disease (MRD) testing using next-generation flow cytometry (NGF)
  • Blood testing for routine monitoring


The ASCENT trial tests early intervention in high-risk smoldering multiple myeloma.


Launched in 2016, the iStopMM project identifies and treats multiple myeloma at the earliest signs of disease. Approximately 80,000 adults over the age of 40 have volunteered to take part, making iStopMM the largest screening project for any type of cancer ever conducted.


Studies are exploring long-term survival and hereditary risk factors in multiple myeloma.


Studies are:

  • Identifying mechanisms of the progression of multiple myeloma.
  • Testing DNA mutations in the blood. 


Singapore is the hub for the clinical trials network in Asia led for the IMF’s Asian Myeloma Network (AMN) program by Prof Wee Joo Chng. A collaboration of eight countries (or regions), the AMN is unique in providing access to novel agents in a clinical trial setting throughout Asia. In addition, research projects appropriate for the region are conducted in an effort to improve outcomes and achieve a cure. 

Linda Huguelet
Linda Huguelet, Chatanooga Multiple Myeloma Networking Group support leader
Diagnosed with myeloma in 2010
Just the thought that it's related to the word 'cure' is so exciting and something that I really didn't think I would see in my lifetime.
Be a Part of the Cure

Your donation allows us to continue to fund efforts to search for a cure. With your help, we are closer than ever.

A group of scientists review a test sample in a medical research lab

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.